The present invention provides compounds and methods of use thereof for the treatment prevention and/or reduction of a risk of a disease disorder or condition in which aldehyde toxicity is implicated in the pathogenesis including ocular disorders skin disorders conditions associated with injurious effects from blister agents and autoimmune inflammatory neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes such as MDA and HNE.